3-81577999-C-T
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_000158.4(GBE1):c.1544G>A(p.Arg515His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000249 in 1,608,922 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000158.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBE1 | NM_000158.4 | c.1544G>A | p.Arg515His | missense_variant | 12/16 | ENST00000429644.7 | NP_000149.4 | |
GBE1 | XR_007095662.1 | n.1672G>A | non_coding_transcript_exon_variant | 12/15 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBE1 | ENST00000429644.7 | c.1544G>A | p.Arg515His | missense_variant | 12/16 | 1 | NM_000158.4 | ENSP00000410833 | P1 | |
GBE1 | ENST00000489715.1 | c.1421G>A | p.Arg474His | missense_variant | 12/16 | 2 | ENSP00000419638 |
Frequencies
GnomAD3 genomes AF: 0.0000461 AC: 7AN: 151966Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000328 AC: 8AN: 243796Hom.: 0 AF XY: 0.0000378 AC XY: 5AN XY: 132394
GnomAD4 exome AF: 0.0000227 AC: 33AN: 1456956Hom.: 0 Cov.: 31 AF XY: 0.0000248 AC XY: 18AN XY: 724628
GnomAD4 genome AF: 0.0000461 AC: 7AN: 151966Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74194
ClinVar
Submissions by phenotype
Glycogen storage disease, type IV Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 25, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | - | This variant has been previously reported as a homozygous or compound heterozygous change in patients with adult onset polyglucosan body disease and glycogen storage disease IV (PMID: 10762170, 12874416, 24248152, 31815882). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.004% (10/275166) and thus is presumed to be rare. The c.1544G>A (p.Arg515His) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. A different missense change at the same codon (p.Arg515Cys) has also been observed in individuals with GBE1-related conditions (PMID: 8613547), which suggests that this may be a clinically significant amino acid residue. Based on the available evidence, the c.1544G>A (p.Arg515His) variant is classified as Pathogenic. - |
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 09, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10762170, 9851430, 12874416, 31815882, 33141444, 28716262, 32685346, 30228975, 38516405, 37269902, 36830903, 24248152) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 03, 2016 | - - |
GBE1-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 23, 2023 | The GBE1 c.1544G>A variant is predicted to result in the amino acid substitution p.Arg515His. This variant has been reported, in the homozygous or compound heterozygous state, in patients with clinical features consistent with later-onset glycogen storage disease type IV (GSD IV) or adult polyglucosan body disease (APBD), and reduced glycogen branching enzyme activity in various tested cell types (Ziemssen et al. 2000. PubMed ID: 10762170; Sindern et al. 2003. PubMed ID: 12874416; Billot et al. 2013. PubMed ID: 23146612; Paradas et al. 2014. PubMed ID: 24248152). It has also been reported, along with the known pathogenic c.986A>C (p.Tyr329Ser) variant, in a patient with features consistent with hereditary spastic paraplegia (Souza et al. 2017. PubMed ID: 28716262). To our knowledge, the c.1544G>A (p.Arg515His) variant has not been reported in patients with infantile onset GSD IV, although a different substitution of the same amino acid (p.Arg515Cys) has been reported in patients with infantile onset GSD IV (Bao et al. 1996. PubMed ID: 8613547; Li et al. 2010. PubMed ID: 20058079). Internally, we have observed the c.1544G>A variant in the compound heterozygous state with a rare GBE1 variant of uncertain significance in a patient with a liver biopsy suggestive of GSD IV. This variant is reported in 0.0084% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-81627150-C-T). This variant is interpreted as likely pathogenic. - |
Adult polyglucosan body disease Pathogenic:1
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 27, 2022 | The p.Arg515His variant in GBE1 has been reported in 4 individuals with adult polyglucosan body disease (APBD) (PMID: 10762170, 24248152, 31815882) and has been identified in 0.008% (2/23806) of African/African American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs201958741). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of the 4 affected individuals, 1 was a compound heterozygote that carried a reported likely pathogenic variants in trans, 1 was a homozygote, and 2 were compound heterozygotes that carried variants of uncertain significance in trans, which increases the likelihood that the p.Arg515His variant is pathogenic (VariationID: 2782; PMID: 10762170, 24248152, 31815882). This variant has also been reported in ClinVar (Variation ID#: 180651) and has been interpreted as pathogenic or likely pathogenic by Invitae, OMIM, GeneDx, EGL Genetic Diagnostics (Eurofins Clinical Diagnostics), and Natera. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for APBD. ACMG/AMP Criteria applied: PP3, PM3_strong, PM2_supporting (Richards 2015). - |
See cases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jan 12, 2022 | ACMG classification criteria: PS4, PM2, PM3, PP3 - |
Adult polyglucosan body neuropathy Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2000 | - - |
Glycogen storage disease, type IV;C1856301:Glycogen storage disease IV, classic hepatic Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 17, 2024 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 515 of the GBE1 protein (p.Arg515His). This variant is present in population databases (rs201958741, gnomAD 0.008%). This missense change has been observed in individual(s) with adult polyglucosan body disease or glycogen storage disease IV (PMID: 10762170, 24248152; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 180651). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GBE1 protein function with a positive predictive value of 95%. This variant disrupts the p.Arg515 amino acid residue in GBE1. Other variant(s) that disrupt this residue have been observed in individuals with GBE1-related conditions (PMID: 8613547, 20058079), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at